Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01052688 · ClinicalTrials.gov registry record
Noninvasive Screening for Affected Pregnancies: Assay Development & Optimization in Affected Pregnancies
A clinical trial, sponsored by Sequenom.
- Completed
- Registry status
- 150
- Enrollment target
NCT01052688 is a clinical trial that has completed, run by Sequenom. The registered enrollment target is 150 participants.
The verdict
NCT01052688 has completed, sponsored by Sequenom.
- COMPLETED
- Registry status
- 150 participants
- Enrollment target
Study Summary
To collect samples for the purpose of developing and optimizing an in vitro noninvasive prenatal diagnostic (NIPD) test. The NIPD test employs circulating cell free (ccff) DNA extracted from whole blood samples collected from women who are pregnant with a fetus previously determined to have a chromosomal abnormality. The NIPD result will be compared to the standard test results obtained from other test methods such as karyotype, FISH, QF-PCR, and/or any commercially available NIPD test.
Interventions
- OTHER Maternal blood draw of 30 to 50ml
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2009-11 |
| Est. Completion | 2021-08-31 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01052688
The ClinicalTrials.gov registry entry for NCT01052688 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 150 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sequenom, which has 26 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Maternal blood draw of 30 to 50ml is the first listed.
NCT01052688 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01052688 about?
NCT01052688 is a clinical study titled "Noninvasive Screening for Affected Pregnancies: Assay Development & Optimization in Affected Pregnancies". To collect samples for the purpose of developing and optimizing an in vitro noninvasive prenatal diagnostic (NIPD) test. The NIPD test employs circulating cell free (ccff) DNA extracted from whole blood samples collected from women who are pregnant with a fetus previously determined to have a chromo...
What is the current status of trial NCT01052688?
This trial is currently completed. The enrollment target is 150 participants. The study started on 2009-11. Estimated completion is 2021-08-31.
What interventions are being tested in trial NCT01052688?
The interventions under investigation include: Maternal blood draw of 30 to 50ml (OTHER).
Who is sponsoring clinical trial NCT01052688?
This trial is sponsored by Sequenom, which has 26 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.